Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Anchiano Therapeutics Announces Closing of $30.5 Million Initial Public Offering | ||
By: Nasdaq / GlobeNewswire - 14 Feb 2019 | Back to overview list |
|
CAMBRIDGE, Mass., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq and TASE: ANCN) (“Anchiano”) today announced that it has closed its initial public offering of 2,652,174 of its American Depositary Shares (“ADSs”), each representing five ordinary shares of Anchiano, at $11.50 per ADS resulting in gross proceeds of $30.5 million. The ADSs began trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “ANCN” on February 12, 2019. The underwriters have been granted a 30-day option to purchase up to an additional 397,826 ADSs offered by Anchiano to cover over-allotments, if any. In the offering, Oppenheimer & Co. Inc. acted as the sole book-running manager, Ladenburg Thalmann acted as lead manager and LifeSci Capital LLC acted as co-manager. The offering has been made only by means of a prospectus, copies of which can be obtained from Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad St., 26th Floor, New York, NY 10004, by telephone at (212) 667-8055 or by email at EquityProspectus@opco.com. A registration statement relating to these securities was filed with and declared effective by the U.S. Securities and Exchange Commission on February 11, 2019. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to their registration or qualification under the securities laws of any such state or jurisdiction. About Anchiano Forward Looking Statements Company Contact: Investor Contact: |
||
|
||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |